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Insulin-like growth factor (IGF)-I induces growth in pancreatic cancer cells and blockade of the IGF-I receptor has antitumour activity.
The association of plasma IGF-I and IGF binding protein-3 (IGFBP-3) with pancreatic cancer risk has been investigated in two small
studies, with conflicting results. We conducted a nested case–control study within four large, prospective cohorts to investigate
whether prediagnostic plasma levels of IGF-I, IGF-II, and IGFBP-3 were associated with pancreatic cancer risk. Plasma levels in 212
cases and 635 matched controls were compared by conditional logistic regression, with adjustment for other known pancreatic
cancer risk factors. No association was observed between plasma levels of IGF-I, IGF-II, or IGFBP-3 and incident diagnosis of
pancreatic cancer. Relative risks for the highest vs the lowest quartile of IGF-I, IGF-II, and IGFBP-3 were 0.94 (95% confidence interval
(CI), 0.60–1.48), 0.96 (95% CI, 0.61–1.52), and 1.21 (95% CI, 0.75–1.92), respectively. The relative risk for the molar ratio of IGF-I
and IGFBP-3, a surrogate measure for free IGF-I, was 0.84 (95% CI, 0.54–1.31). Additionally, no association was noted in stratified
analyses or when requiring longer follow-up. In four prospective cohorts, we found no association between the risk of pancreatic
cancer and prediagnostic plasma levels of IGF-I, IGF-II, or IGFBP-3.
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The insulin-like growth factor (IGF) axis has been implicated in
the development of several malignancies (Renehan et al, 2004).
Insulin-like growth factor-I is a hormone and growth factor
produced predominantly in the liver under the regulation of
growth hormone, but also produced locally in multiple tissue
types. Insulin-like growth factor-II is structurally similar to IGF-I,
primarily produced in the liver, and maternally imprinted
(Khandwala et al, 2000). More than 80% of circulating IGF-I and
IGF-II are bound to IGF binding protein-3 (IGFBP-3), in a protein
complex that is confined to the vascular compartment (Firth and
Baxter, 2002). Tissue IGF bioactivity is thought to be determined
by free IGF, the component of IGF not bound to IGF binding
proteins, which binds to the IGF-I receptor (IGF-IR) on the target
cell surface (Jones and Clemmons, 1995). Insulin-like growth
factor-I and IGF-IR are highly expressed in pancreatic cancer cell
lines, where initiation of intracellular signalling through IGF-IR
leads to decreased apoptosis and increased proliferation, invasion,
and expression of mediators of angiogenesis (Ohmura et al, 1990;
Bergmann et al, 1995; Stoeltzing et al, 2003; Zeng et al, 2003; Neid
et al, 2004).
High plasma levels of IGF-I and low levels of IGFBP-3 are
associated with the development of prostate (Chan et al, 1998),
colorectal (Ma et al, 1999), and premenopausal breast (Hankinson
et al, 1998) cancer. In addition, loss of imprinting at the IGF-II
locus leads to increased expression of IGF-II and higher rates of
malignancy (Cui et al, 2003; Feinberg, 2004; Sakatani et al, 2005).
Two small, nested case–control studies of IGF-I, IGFBP-3, and
pancreatic cancer risk have yielded conflicting results (Lin et al,
2004; Stolzenberg-Solomon et al, 2004).
To further investigate whether plasma IGF-I, IGF-II, and
IGFBP-3 levels are associated with the risk of pancreatic
cancer, we performed a nested case–control study using the
combined resources of four large prospective cohort studies,
with blood samples collected before cancer diagnosis. We
hypothesized that elevated levels of IGF-I and IGF-II and/or depressed
levels of IGFBP-3 would predict an increased risk of pancreatic
cancer.
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sMATERIALS AND METHODS
Subjects
Pancreatic cancer cases and matched controls through 2003 were
drawn from four prospective cohort studies: the Nurses’ Health
Study (NHS), Health Professionals Follow-up Study (HPFS),
Physicians’ Health Study (PHS), and Women’s Health Initiative
(WHI). The NHS was initiated in 1976 when 121701 US female
registered nurses aged 30–55 responded to a mailed questionnaire
regarding individual characteristics, habits, and medical history.
The HPFS began in 1986 when 51529 male health professionals
aged 40–76 years responded to a similarly mailed questionnaire.
The PHS was initiated in 1982 as a randomized clinical trial
evaluating aspirin and b-carotene among 22071 male physicians
aged 40–84 years. The WHI observational component is a multi-
centre cohort study of 93676 postmenopausal women aged 50–79
years, enrolled between 1994 and 1998. In each of these cohort
studies, regular follow-up questionnaires were mailed to partici-
pants every 1–2 years to update exposure data and medical
history. Deaths among non-respondents were actively ascertained.
All participants provided consent upon enrollment. The current
study was approved by the Human Research Committee at
Brigham and Women’s Hospital, Boston, MA, USA.
If a participant (or next of kin for decedents) reported a
diagnosis of pancreatic cancer, the diagnosis was confirmed by
medical record and pathology report review. If the primary cause
of death on a death certificate was a previously unreported or
unconfirmed case of pancreatic cancer, family members were
contacted for permission to retrieve medical records and confirm
the diagnosis. Most deaths in these cohorts were reported by
family members or by the postal service in response to follow-up
questionnaires. In addition, searches of the National Death Index
were conducted for non-responders; this method has a sensitivity
of 98% or greater in identifying decedents (Rich-Edwards et al,
1994).
In each cohort study, blood samples drawn from participants
were kept chilled until processing, separated into plasma,
erythrocytes, and buffy coat, and stored as multiple aliquots in
liquid nitrogen freezers. During storage, precautions were taken to
ensure that no specimens thawed or warmed substantially. Blood
was drawn from 18225 men in the HPFS between 1993 and 1995,
32826 women in the NHS from 1989 to 1990, 14916 men in the
PHS from 1982 to 1984, and 93676 women in the WHI between
1994 and 1998.
Eligibility criteria for potential cases included no prior history of
malignancy (other than non-melanoma skin cancer), available
plasma sample, and two or more years between plasma collection
and pancreatic cancer diagnosis. At the time of data set creation,
the diagnosis of pancreatic cancer was confirmed by medical
record review for all but four reported cases. Controls were
required to have an available plasma sample and no cancer
diagnosis (other than non-melanoma skin cancer). Three controls
were matched to each case based on year of birth, smoking status
(current, past, never), prospective cohort, month of blood draw,
and fasting status at time of blood draw.
Plasma assays of IGF-I, IGF-II, and IGFBP-3
Plasma levels of IGF-I, IGF-II, and IGFBP-3 were assayed in the
laboratory of Dr Michael N Pollak (Jewish General Hospital and
McGill University) by enzyme-linked immunosorbent assay with
reagents from Diagnostic Systems Laboratory (Webster, TX, USA).
Plasma samples from cases and matched control subjects were
assayed in the same batch to minimize interassay variability, and
quality control samples were inserted randomly. Laboratory
personnel were unable to distinguish among case, control, and
quality control samples. The mean intra-assay coefficients of
variation for IGF-I, IGF-II, and IGFBP-3 from the blinded quality
control samples were o11% for IGF-I, o6% for IGF-II, and o5%
for IGFBP-3.
Statistical analysis
We square root transformed the plasma biomarkers to improve
normality and compared values for cases and controls using paired
t-tests. Continuous and categorical covariates were compared
using Wilcoxon signed rank, and w
2 tests, respectively. For the
plasma biomarkers, all quartile cut-points were generated among
the controls only and were determined separately for each
prospective cohort. Spearman’s correlation coefficients were
calculated to examine the relationships among IGF-I, IGF-II,
IGFBP-3, and selected covariates.
We computed odds ratios to estimate relative risks for the
association of IGF-I, IGF-II, and IGFBP-3 and pancreatic cancer
risk using conditional logistic regression. We also examined the
molar ratio of IGF-I to IGFBP-3, as a possible surrogate for
free IGF-I (for IGF-I, 1ngml
 1¼0.130nM; and for IGFBP-3,
1ngml
 1¼0.036nM). Tests for trend using two-sided P-values
were calculated by entering the quartile-specific median values for
IGF-1, IGF-II, IGFBP-3, and molar ratio of IGF-I and IGFBP-3 as
continuous variables in logistic regression models. To confirm
that data from the four cohorts could be combined, we utilized
Cochran’s Q to test for heterogeneity between cohorts.
We adjusted for covariates that were associated with pancreatic
cancer risk in these cohorts, including body mass index (BMI,
weight in kilograms/(height in meters)
2), level of physical activity,
history of diabetes mellitus, and history of regular multivitamin
use. Body mass index and level of physical activity were included
in models after division into quartiles. Other covariates, such as
height, intake of vitamin D, intake of calcium, and total energy
intake, were not included, as they were not consistently associated
with pancreatic cancer risk across the cohorts.
Stratified analyses were conducted using unconditional logistic
regression. We sequentially excluding cases and matched controls,
with less than 4, 6, or 8 years between plasma collection and cancer
diagnosis to evaluate whether the influence of IGF-I, IGF-II, or
IGFBP-3 would change with longer follow-up. All statistical
analyses were performed using the SAS 8.2 statistical package
(SAS Institute, Cary, NC, USA) and all P-values are two sided.
RESULTS
From the four cohorts, 212 cases of pancreatic cancer were
identified in participants who had provided blood two or more
years before cancer diagnosis. Based on the matching factors of
year of birth, smoking status, prospective cohort, month of blood
draw, and fasting status, 636 control participants were chosen. One
control developed pancreatic cancer and was removed from the
study, resulting in 212 cases and 635 controls available for analysis.
No samples fell below the lowest concentration on the standard
curves for the IGF-I, IGF-II, or IGFBP-3 assays. The comparison of
IGF-I, IGF-II, and IGFBP-3 data from the four cohorts using
Cochran’s Q test for heterogeneity resulted in P-values of 0.58,
0.91, and 0.48, respectively, supporting the combined analysis of
plasma marker data.
Baseline characteristics of the cases and matched controls are
shown in Table 1. Participants who developed pancreatic cancer
had a slightly higher BMI and were less likely to perform regular
physical activity. No statistically significant differences were noted
in other covariates or the plasma biomarkers. Spearman’s
correlation coefficients demonstrated a significant positive corre-
lation of IGF-I with IGFBP-3, IGF-I:IGFBP-3 molar ratio, and
height, and a significant inverse correlation with age. IGF-II
was positively correlated with IGF-I and IGFBP-3, while little
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scorrelation was noted with the other covariates (correlation
coefficients available in Table 1 of Supplementary Material).
Covariates related to the risk of pancreatic cancer with a P-value
of less than 0.20 were included in multivariate analyses. Before
and after adjustment for these covariates (BMI, level of physical
activity, history of diabetes mellitus and regular multivitamin use),
IGF-I, IGFBP-3, the IGF-I:IGFBP-3 molar ratio, and IGF-II were
not associated with risk of pancreatic cancer (Table 2). The
adjusted relative risk for the highest quartile of IGF-I compared
with the lowest quartile was 0.94 (95% confidence interval (CI),
0.60–1.48). When the model was also adjusted for IGFBP-3, little
change was noted in this relative risk. The adjusted relative risk for
the highest quartile of IGFBP-3 compared with the lowest quartile
was 1.21 (95% CI, 0.75–1.92), which changed minimally after
inclusion of IGF-I in the multivariate model. In addition, the
adjusted relative risks for the top vs the bottom quartiles of IGF-
I:IGFBP-3 molar ratio and IGF-II were 0.84 (95% CI, 0.54–1.31)
and 0.96 (95% CI, 0.61–1.52), respectively.
To evaluate more extreme levels of IGF-I, IGF-II, and IGFBP-3,
we repeated the analyses after categorizing these plasma markers
into deciles. As compared with participants in the lowest decile,
participants in the highest decile of IGF-I, IGFBP-3, IGF-I:IGFBP-
3 molar ratio, and IGF-II had adjusted relative risks of pancreatic
cancer of 0.98 (95% CI, 0.50–1.93), 1.28 (95% CI, 0.65–2.52), 0.93
(95% CI, 0.46–1.89), and 1.14 (95% CI, 0.58–2.24), respectively.
Additionally, we evaluated the combined effect of IGF-I and
IGFBP-3 on pancreatic cancer risk by categorizing the plasma
markers into tertiles and constructing a 3 3 table. The adjusted
relative risk in the highest tertile of IGF-I and the lowest tertile of
IGFBP-3 was 1.77 (95% CI, 0.25–12.70) compared with those
participants in the lowest tertile of IGF-I and highest tertile of
IGFBP-3. Only 3 cases and 14 controls were located in this extreme
category of simultaneously high IGF-I and low IGFBP-3.
We found no evidence of an association between IGF-I and risk
of pancreatic cancer in subgroups defined by categories of age,
gender, BMI, smoking status, level of physical activity (Table 3), or
regular multivitamin use. Similarly, no associations were noted in
these subgroups for stratified analyses of IGFBP-3, IGF-I:IGFBP-3
molar ratio, and IGF-II (data not shown). Moreover, our results
remained unchanged after excluding participants with a history of
diabetes mellitus (data not shown).
To assess for a possible influence of the IGF axis after longer
periods of follow-up and to rule out an effect of preclinical disease
on IGF levels, we sequentially excluded cases and matched
controls, requiring longer periods of time between plasma
collection and pancreatic cancer diagnosis. No association was
noted between IGF-I, IGFBP-3, IGF-I:IGFBP-3 molar ratio, or
IGF-II and risk of pancreatic cancer when 2, 4, 6, or 8 years were
required between plasma collection and cancer diagnosis (Table 4).
DISCUSSION
In this prospective, nested case–control study, we found no
evidence that the risk of pancreatic cancer was influenced by
prediagnostic plasma levels of IGF-I, IGF-II, or IGFBP-3. No
association was observed when these serum markers were analysed
by comparing the top vs the bottom quartiles or when more
extreme values were analysed by comparing the top vs the bottom
deciles. In addition, no association was noted within selected
subgroups or when longer follow-up was required between plasma
collection and cancer diagnosis. The molar ratio of IGF-I and
IGFBP-3 also was not associated with the development of
pancreatic cancer.
Two smaller studies have evaluated the association of IGF-I and
IGFBP-3 with pancreatic cancer risk (Lin et al, 2004; Stolzenberg-
Solomon et al, 2004). A study of 93 pancreatic cancer cases from
the Alpha-Tocopherol, b-Carotene (ATBC) Cancer Prevention
Study of Finnish, male smokers found no association between
IGF-I, IGFBP-3, or IGF-I:IGFBP-3 molar ratio and the risk of
pancreatic cancer (Stolzenberg-Solomon et al, 2004). A study
of 69 pancreatic cancer cases from the Japan Collaborative
Cohort Study for Evaluation of Cancer Risk reported a
nonsignificant increase in the risk of death from pancreatic cancer
in the top vs the bottom quartile of IGF-I and IGFBP-3 (RR 2.31,
95% CI 0.70–7.64, and RR 2.53, 95% CI 0.93–6.85, respectively),
which was attenuated when both plasma biomarkers were included
in multivariate models (Lin et al, 2004). Thus, as in the current
study, prior analyses of different patient populations have
not supported a significant association between prediagnostic
Table 1 Baseline characteristics of pancreatic cancer cases and matched
controls
Variable
Cases
(n¼212)
Controls
(n¼635) P-value
a
Cohort Matched
HPFS 32 96
PHS 57 171
NHS 49 146
WHI 74 222
Age (years) 62.278.3 61.778.4 Matched
Gender Matched
Female (%) 58 58
Male (%) 42 42
BMI (kgm
 2) 26.674.8 26.175.2 0.05
Height (inches) 66.873.9 66.973.9 0.78
Smoking status Matched
Never (%) 38 39
Past (%) 43 45
Current (%) 18 17
History of diabetes mellitus 0.11
Yes (%) 7 4
No (%) 93 96
Physical activity
b 0.05
Low (%) 60 53
High (%) 40 47
History of regular
multivitamin use
0.10
Yes (%) 42 36
No (%) 58 64
Vitamin D intake (IU)
c 400.57276.8 387.47274.3 0.62
Total energy intake (kcal)
c 1675.47554.8 1738.97618.7 0.35
Fasting status Matched
p8h or unknown (%) 30 30
48h (%) 70 70
IGF-I (ngml
 1) 164.4766.2 167.7768.2 0.49
IGFBP-3 (ngml
 1) 4340.97953.8 4325.67872.5 0.92
IGF-1:IGFBP-3 molar ratio 0.13670.045 0.13970.045 0.36
IGF-II (ngml
 1) 1058.77256.0 1060.17229.4 0.82
HPFS¼Health Professionals Follow-up Study; PHS¼Physicians’ Health Study;
NHS¼Nurses’ Health Study; WHI¼Women’s Health Initiative; BMI¼ body mass
index; IGF-I¼insulin-like growth factor-I; IGFBP-3¼insulin-like growth factor binding
protein-3; IGF-II¼insulin-like growth factor-II. Mean7standard deviation.
aIGF-I,
IGFBP-3, IGF-I:IGFBP-3 molar ratio, and IGF-II were square root transformed to
improve normality and analysed using paired t-tests. Covariates were analysed using
Wilcoxon signed rank for continuous variables, and w
2 for categorical variables.
bBelow (low) or above (high) the median level of physical activity.
cHPFS, NHS, and
WHI participants.
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sTable 2 Relative risk (95% CI) of pancreatic cancer according to quartile of IGF-I, IGFBP-3, IGF-I:IGFBP-3 molar ratio, and IGF-II
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value, trend
IGF-I
Median (ngml
 1) 97.1 142.0 177.2 242.2
Cases/controls 65/157 42/160 50/158 55/160
RR
a 1.0 0.63 (0.41–0.99) 0.78 (0.51–1.19) 0.83 (0.54–1.28) 0.57
RR
b 1.0 0.67 (0.42–1.06) 0.84 (0.54–1.30) 0.94 (0.60–1.48) 0.97
RR
c 1.0 0.62 (0.38–1.00) 0.73 (0.44–1.21) 0.78 (0.44–1.38) 0.56
IGFBP-3
Median (ngml
 1) 3345.3 4043.6 4539.4 5290.2
Cases/controls 51/158 53/158 50/158 58/161
RR
a 1.0 1.03 (0.66–1.62) 0.98 (0.63–1.54) 1.13 (0.72–1.77) 0.66
RR
b 1.0 1.06 (0.67–1.69) 1.11 (0.70–1.76) 1.21 (0.75–1.92) 0.42
RR
d 1.0 1.19 (0.73–1.95) 1.29 (0.76–2.19) 1.38 (0.76–2.51) 0.28
IGF-I:IGFBP-3 molar ratio
Median 0.09 0.11 0.13 0.19
Cases/controls 68/157 41/160 50/158 53/160
RR
a 1.0 0.60 (0.38–0.93) 0.74 (0.48–1.12) 0.77 (0.50–1.19) 0.49
RR
b 1.0 0.62 (0.39–0.97) 0.79 (0.51–1.22) 0.84 (0.54–1.31) 0.80
IGF-II
Median (ngml
 1) 802.8 986.2 1116.7 1335.0
Cases/controls 56/161 47/158 59/159 50/157
RR
a 1.0 0.86 (0.55–1.33) 1.06 (0.70–1.62) 0.91 (0.59–1.42) 0.88
RR
b 1.0 0.89 (0.57–1.40) 1.12 (0.72–1.73) 0.96 (0.61–1.52) 0.93
CI¼confidence interval; IGF-I¼insulin-like growth factor-I; IGFBP-3¼insulin-like growth factor binding protein-3; IGF-II¼insulin-like growth factor-II.
aMatched for year of birth,
smoking status, fasting status, month of blood draw, and prospective cohort.
bMatched for year of birth, smoking status, fasting status, month of blood draw and prospective
cohort, and adjusted for BMI, regular multivitamin use, level of physical activity, and history of diabetes.
cMatched for year of birth, smoking status, fasting status, month of blood
draw and prospective cohort, and adjusted for BMI, regular multivitamin use, level of physical activity, history of diabetes, and IGFBP-3.
dMatched for year of birth, smoking status,
fasting status, month of blood draw and prospective cohort, and adjusted for BMI, regular multivitamin use, level of physical activity, history of diabetes, and IGF-I.
Table 3 Relative risk of pancreatic cancer according to quartile of insulin-like growth factor-I (IGF-I) in subgroups defined by selected variables
Covariate Cases/controls Quartile 1 Quartile 2 Quartile 3 Quartile 4 95 % CI
a of Quartile 4 P-value, trend
Age (years)
b
p62 102/335 1.0 0.74 0.86 0.92 0.48–1.78 0.98
462 110/300 1.0 0.59 0.87 1.00 0.54–1.88 0.83
Gender
Male 89/267 1.0 0.75 0.80 1.40 0.69–2.84 0.29
Female 123/368 1.0 0.63 0.86 0.76 0.42–1.38 0.53
BMI (kgm
 2)
o25 88/306 1.0 0.88 0.87 0.75 0.37–1.51 0.43
X25 124/329 1.0 0.59 0.81 1.17 0.65–2.11 0.42
Smoking status
Never 81/243 1.0 0.78 0.77 1.00 0.47–2.13 0.97
Past 92/283 1.0 0.75 0.83 1.06 0.54–2.10 0.81
Current 39/107 1.0 0.38 0.85 0.69 0.22–2.16 0.79
Level of activity
c
Low 128/334 1.0 0.62 0.86 0.96 0.52–1.76 0.89
High 84/301 1.0 0.71 0.63 0.86 0.44–1.69 0.73
Multivitamin use
No 122/408 1.0 0.84 0.88 0.88 0.49–1.59 0.74
Yes 90/227 1.0 0.53 0.86 1.08 0.53–2.21 0.62
IGFBP-3
d
Low 104/316 1.0 0.44 0.82 0.91 0.36–2.28 0.43
High 108/319 1.0 1.26 0.95 1.19 0.48–2.97 0.74
CI¼confidence interval; BMI¼body mass index; IGFBP-3¼insulin-like growth factor binding protein-3. Multivariate relative risks adjusted for year of birth, smoking status, fasting
status, prospective cohort, BMI, level of physical activity, regular multivitamin use, and history of diabetes mellitus. In each stratified analysis, the stratification variable was excluded
from the model.
aNinety-five percent confidence interval.
bSixty-two years of age is the median age for controls.
cHigh is above the median level, while low is below the median
level of physical activity.
dHigh is above the median level, while low is below the median level of IGFBP-3.
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splasma levels of IGF-I or IGFBP-3 and the risk of pancreatic
cancer.
Our study has several strengths, which lend further credibility to
its negative findings. First, with 212 cases, our analysis includes
more than the combined number of cases in the previous two
prospective studies. Second, our cases are drawn from four
different prospective cohort studies, increasing the generalizability
of our results. Third, the collection of plasma and extensive
exposure data before cancer diagnosis limits the potential
influence of subclinical malignancy on our results. Finally, the
ability to draw matched controls from a large pool of participants
in each cohort study limits the potential for selection bias.
A limitation of our study is an inability to correlate the risk of
pancreatic cancer with long-term levels of these plasma markers,
since IGF-I, IGF-II, and IGFBP-3 were measured at a single point
in time. However, previous evidence suggests that IGF levels are
relatively stable over time in adults, such that a single measure-
ment is a reasonable proxy for levels of long-term exposure
(Goodman-Gruen and Barrett-Connor, 1997; Chan et al, 1998;
Platz et al, 1999). Moreover, previous studies in these cohorts
indicate that baseline plasma levels of IGF-I and IGFBP-3 are
significantly associated with the risk of several other malignancies
(Chan et al, 1998; Hankinson et al, 1998; Ma et al, 1999).
If a long latency period is required to see an effect of IGF-I, IGF-
II, or IGFBP-3, then a second limitation of our study could be an
inadequate duration of follow-up. However, the lack of association
between IGF-I, IGF-II, or IGFBP-3 and pancreatic cancer in cases
and matched controls with eight or more years between plasma
collection and cancer diagnosis is reassuring that we are not
missing a large effect of these plasma markers. In addition, the
nested case–control study from the ATBC with up to 12.7 years
between plasma collection and cancer diagnosis did not observe
such an association (Stolzenberg-Solomon et al, 2004). Finally, our
study measures plasma levels of IGF-I, IGF-II, and IGFBP-3 and
not local tissue levels in the pancreas. Therefore, if circulating
levels do not reflect local levels of these proteins, the observed
odds ratios may not represent the true activity of IGF in the
pancreas. Since circulating levels of IGF-I and IGFBP-3 have been
correlated with the risk of several other malignancies (Renehan
et al, 2004), our results do demonstrate that a similar association
with pancreatic cancer risk is unlikely to be present in participants
from our four cohorts.
Although tobacco use and increasing age are the best-defined
risk factors for pancreatic cancer, several environmental and
lifestyle factors have emerged that may be associated with this
malignancy (Fuchs et al, 1996; Li et al, 2004). Studies have
implicated obesity, lack of exercise, dietary glycemic load (an
estimation of post-prandial glucose response), and diabetes
mellitus as risk factors for pancreatic cancer (Gapstur et al,
2000; Michaud et al, 2001, 2002; Eberle et al, 2005; Huxley et al,
2005; Larsson et al, 2005). The mechanisms by which these factors
increase cancer risk have been hypothesized to involve insulin and
the insulin-like growth factor axis, which are intimately involved
in glucose and energy homeostasis (Kaaks and Lukanova, 2001;
Jerome et al, 2003).
Pancreatic ductal cells are exposed to insulin concentrations that
are 20-fold higher than those present in the systemic circulation,
due to the close proximity of these cells to the insulin-secreting
cells of the islets of Langerhans (Hennig et al, 2004). Experimental
studies have demonstrated that insulin may have growth-promoting
effects on pancreatic ductal adenocarcinoma cells (Fisher et al,
1996; Wang et al, 1998; Ding et al, 2000) and that peripheral
insulin resistance promotes pancreatic ductal carcinogenesis
(Bell et al, 1988; Schneider et al, 2001). Additionally, treatment
with metformin, an oral hypoglycemic agent that leads to
decreases in peripheral insulin resistance and pancreatic insulin
production, may prevent the development of malignant lesions
(Schneider et al, 2001). These experimental studies support a
biologic mechanism whereby elevated concentrations of serum
insulin may promote the development of pancreatic ductal
carcinoma. Further support for this mechanisms is lent by
epidemiologic studies in which prediagnostic elevations in
fasting serum glucose, post-load plasma glucose, and fasting
serum insulin have been associated with an elevated risk of
pancreatic cancer (Gapstur et al, 2000; Jee et al, 2005; Stolzenberg-
Solomon et al, 2005).
Experimental data also support a role for the insulin-like growth
factor axis in the pathogenesis of pancreatic cancer. In vitro studies
have demonstrated that IGF-I and IGF-II are potent mitogens for
cultured human pancreatic cancer cells (Ohmura et al, 1990;
Bergmann et al, 1995; Stoeltzing et al, 2003; Zeng et al, 2003) and
that IGF binding proteins can have opposing actions, in part by
binding IGF-I and IGF-II (Rechler, 1997), but also by direct
inhibitory effects on target cells (Rajah et al, 1997). The IGF axis
also interacts with the insulin pathway, as elevated levels of insulin
increase free, biologically active IGF-I, and alter concentrations of
several IGF binding proteins (Giovannucci, 2003). For several
malignancies, both elevated levels of circulating insulin and IGF-I
have been associated with increased risk (Kaaks et al, 2000; Wei
et al, 2005). Results from the current study and studies of insulin
and insulin resistance suggest that pancreatic carcinogenesis may
be influenced by circulating insulin levels, whereas plasma levels of
IGF-I, IGF-II, and IGFBP-3 may have little effect on the long-term
risk for this malignancy. But given the intimate relationship of
multiple components of the IGF axis and insulin, the IGF axis may
still play a role in the pathogenesis of pancreatic cancer that was
not elucidated in the current study. Further studies of the
interactions of insulin and the IGF axis in the pathogenesis of
pancreatic cancer should help to advance our understanding of the
Table 4 Relative risk of pancreatic cancer according to time from plasma
collection to pancreatic cancer diagnosis by quartiles of IGF-I, IGFBP-3,
IGF-I:IGFBP-3 molar ratio, and IGF-II
a
Quartile
1
Quartile
2
Quartile
3
Quartile
4
95% CI
a
for
Quartile
4
P-value,
trend
IGF-I (years)
X2 1.0 0.67 0.82 0.95 0.61–1.46 0.96
X4 1.0 0.68 1.03 0.73 0.43–1.25 0.45
X6 1.0 0.73 1.02 0.69 0.35–1.37 0.42
X8 1.0 0.74 1.12 0.79 0.35–1.81 0.75
IGFBP-3 (years)
X2 1.0 1.08 1.08 1.27 0.82–1.98 0.29
X4 1.0 0.67 0.92 1.06 0.64–1.74 0.64
X6 1.0 0.53 1.05 0.88 0.47–1.67 0.96
X8 1.0 0.46 0.83 0.86 0.40–1.86 0.94
IGF-I:IGFBP-3 molar ratio (years)
X2 1.0 0.64 0.77 0.85 0.55–1.32 0.82
X4 1.0 0.73 0.83 0.73 0.43–1.23 0.34
X6 1.0 0.67 0.70 0.83 0.44–1.58 0.78
X8 1.0 0.80 0.62 1.03 0.47–2.22 0.82
IGF-II (years)
X2 1.0 0.86 1.07 1.00 0.64–1.57 0.81
X4 1.0 0.65 0.75 0.94 0.57–1.55 0.90
X6 1.0 0.62 0.74 0.85 0.45–1.60 0.68
X8 1.0 0.58 0.76 0.71 0.33–1.55 0.46
CI¼confidence interval; IGF-I¼insulin-like growth factor-I, IGFBP-3¼insulin-like
growth factor binding protein-3, IGF-II¼insulin-like growth factor-II. Multivariate
relative risks are adjusted for year of birth, smoking status, fasting status, prospective
cohort, regular multivitamin use, level of physical activity, history of diabetes mellitus,
and BMI.
aNinety-five percent CI.
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